Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors.
Apoptosis
/ drug effects
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Colchicine
/ metabolism
Drug Design
Drug Evaluation, Preclinical
Enzyme Activation
ErbB Receptors
/ antagonists & inhibitors
HeLa Cells
Humans
Membrane Potential, Mitochondrial
/ drug effects
Microtubules
/ drug effects
Poly(ADP-ribose) Polymerases
/ metabolism
Polymerization
Pyrimidines
/ chemistry
Reactive Oxygen Species
/ metabolism
Tubulin
/ metabolism
Vascular Endothelial Growth Factor Receptor-2
/ antagonists & inhibitors
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
14 02 2019
14 02 2019
Historique:
pubmed:
12
1
2019
medline:
4
3
2020
entrez:
12
1
2019
Statut:
ppublish
Résumé
The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3',4',5'-trimethoxyanilino)thieno[3,2- d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3',4',5'-trimethoxyanilino)-6-( p-tolyl)thieno[3,2- d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC
Identifiants
pubmed: 30633509
doi: 10.1021/acs.jmedchem.8b01391
doi:
Substances chimiques
Pyrimidines
0
Reactive Oxygen Species
0
Tubulin
0
Poly(ADP-ribose) Polymerases
EC 2.4.2.30
ErbB Receptors
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM